Broluzumab Biosimilars Market

Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.

Broluzumab Biosimilars Market aims to provide a comprehensive presentation of the global market for Broluzumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Broluzumab Biosimilars. Broluzumab Biosimilars Market contains market size and forecasts of Broluzumab Biosimilars in global, including the following market information:

Global Broluzumab Biosimilars Market Revenue, 2018-2023, 2024-2032, ($ millions)

Global Broluzumab Biosimilars Market Sales, 2018-2023, 2024-2032, (K Units)

Global top five Broluzumab Biosimilars companies in 2022 (%)

The global Broluzumab Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.

Beovu Segment to Reach $ Million by 2029, with a % CAGR in next six years.

The global key manufacturers of Broluzumab Biosimilars include Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. in 2022, the global top five players have a share approximately % in terms of revenue.

We surveyed the Broluzumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Broluzumab Biosimilars Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)

Global Broluzumab Biosimilars Market Segment Percentages, by Type, 2022 (%)

Beovu

Vsiqq

Others

Global Broluzumab Biosimilars Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)

Global Broluzumab Biosimilars Market Segment Percentages, by Application, 2022 (%)

ARMD

Kaposi Sarcoma

Glioblastoma

Global Broluzumab Biosimilars Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)

Global Broluzumab Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Broluzumab Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)

Key companies Broluzumab Biosimilars revenues share in global market, 2022 (%)

Key companies Broluzumab Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)

Key companies Broluzumab Biosimilars sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Genentech

Roche

Pfizer

Sartorius

Eli Lilly

Bayer

Amgen

PlantForm

PharmaPraxis

Samsung Bioepis

Centus

Cadila Pharmaceuticals

Dr Reddy's

Aurobindo Pharma

Biocad

MAbxience

Hetero

Biocon

Kirin Biologics

Mylan

BeiGene

Innovent

Qilu Pharmaceutical

Hengrui Pharmaceuticals

Hisun Pharmaceutical

TOT BIOPHARM

Luye Pharmaceutical

Henlius

Outline of Major Chapters:

Chapter 1: Introduces the definition of Broluzumab Biosimilars, market overview.

Chapter 2: Global Broluzumab Biosimilars market size in revenue and volume.

Chapter 3: Detailed analysis of Broluzumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Broluzumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Global Broluzumab Biosimilars capacity by region & country.

Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 11: The main points and conclusions of the report.